No -- the chart below is not a misprint. Volatility is going through the roof in Human Genome Sciences (HGSI). It's binary event time next week, as Steven Sears explains in the Striking Price: 

Leerink Swann has been the loudest supporter of Human Genome Sciences (HGSI). The boutique is now saying the biggest impediment to HGSI becoming the next big-cap biotech -- presumably a la Amgen (AMG

Back on February 2, I wrote about the convertible bonds of Human Genome Sciences (HGSI), long known as a big but dwindling bank account with a chancy pipeline. The company's anthrax product was bring

Large-cap biotech outperformed the market in 2008, performing slight better than half as bad as the rest of the market. The development-stage companies we cover fared much worse. Bio-Century noted in

The Securities and Exchange Commission may require some US companies to switch to international accounting rules by 2014. The SEC says the change will make American companies more competitive in the

As the pendulum swings between greed and fear, investors typically behave in 1 of 2 ways: They either become over-enthusiastic during bull markets and over-despondent as the bear’s growl grows

Dell (DELL) says price cuts boosted second quarter sales, but cut profits 17%. Dell’s profit dropped to $616 million, or $0.31 per share, from $746 million, or $0.32, for the same period a year

Marvell Lower on Slower SalesShares of Marvell Technology (MRVL) are lower this morning after the company gave a forecast that indicated sales growth is slowing. Bloomberg reports the maker of chips

As stockholders sweep up the remnants of IndyMac and the FDIC continues to add to its list of troubled banks (Wachovia (WB), Washington Mutual (WM) and Zions Bancorp (ZION)) financial insti

A summer has passed since I made the vow to become a more mindful spender.The verdict: Room for improvement.The plan I laid out in May was to switch from debit card to cash for most of my day-to-day